Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...
BioSpace7d
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...
Physician's Weekly3d
GLP-1 Receptor Agonists and Hematologic Cancer Risk in Type 2 Diabetes
The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...
JD Supra11d
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs
Glucagon-like peptide-1 (GLP-1) was first discovered in the 1980s as a regulator of glucose levels. Further research led to the creation of a stabilized GLP-1RA called semaglutide, the active ...
The Cardiology Advisor13d
GLP-1 Receptor Agonists May Have Broader Range of Benefits, Risks
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
Yahoo Finance10d
Biolexis Therapeutics Unlocks a New Frontier in GLP-1 Receptor Activation
structure of BLX-7006, its first-in-class oral small-molecule GLP-1 receptor agonist. This breakthrough confirms a completely novel allosteric activation mechanism for the GLP-1 receptor ...
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The issuer is solely responsible for the content of this announcement.
Endocrinology Advisor11d
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.